• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Novavax COVID Vaccine 140 Million Dose Order Canceled by Japan, Takeda Reveals

Article

In 2021, Takeda announced a partnership with Novavax to manufacture 150 million doses of the Nuvaxovid COVID-19 vaccine; however, the Japanese government has canceled its order for the remaining 141.76 million doses due to low demand.

Japan's cancellation of the Novavax vaccine order will not significantly impact Takeda's finances and the company is not altering its full-year consolidated forecasts.

Related Videos
Related Content